Literature DB >> 3427559

Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients.

A Baruzzi1, M Contin, R Riva, G Procaccianti, F Albani, C Tonello, E Zoni, P Martinelli.   

Abstract

The influence of meal ingestion time on rate and extent of oral levodopa absorption was evaluated in a group of 17 patients, after administration of their usual second daily dose of levodopa plus carbidopa (Sinemet 10:1) or benserazide (Madopar 4:1). Standard meals were consumed by the patients after they had fasted 15-17 h, on one occasion 30 min before ingestion of the levodopa "study dose" and, at another time, 2 h after ingestion of the same dose. This study dose, ranging from 50 to 250 mg levodopa, was given to the patients at 11 a.m., 4 h after their first morning dose. Time to peak plasma levodopa concentration increased threefold (from 45 +/- 23 to 134 +/- 76 min, p less than 0.001), when levodopa was administered after meals. Area under the 6-h plasma concentration-time curve for levodopa was decreased in 10 subjects, unchanged in three and higher in four after ingestion of meals, the latter finding probably resulting from an erratic absorption even at fasting. On the whole, levodopa absorption proved significantly lower (p less than 0.01), on the average 15%. Similarly, peak plasma levodopa concentrations were lower in 12 patients, unchanged in two, and higher in three, with an overall significant decrease (p less than 0.001) of 30% on the average. The data confirm the importance of meal ingestion time in relation to levodopa dose as a determinant of drug absorption.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3427559     DOI: 10.1097/00002826-198712000-00004

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  18 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers.

Authors:  D R Robertson; I Higginson; B S Macklin; A G Renwick; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

4.  Gastric emptying in healthy volunteers after multiple doses of levodopa.

Authors:  D G Waller; C Roseveare; A G Renwick; B Macklin; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

Review 5.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Dopaminergic modulation of the exploration/exploitation trade-off in human decision-making.

Authors:  Karima Chakroun; David Mathar; Antonius Wiehler; Florian Ganzer; Jan Peters
Journal:  Elife       Date:  2020-06-02       Impact factor: 8.140

7.  Nutritional therapies in Parkinson's disease.

Authors:  Marian L Evatt
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

Review 8.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 9.  Drug-food interactions in hospitalised patients. Methods of prevention.

Authors:  I Gauthier; M Malone
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

10.  Clinical aspects of palliative care in advanced Parkinson's disease.

Authors:  Johan Lokk; Ahmad Delbari
Journal:  BMC Palliat Care       Date:  2012-10-25       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.